slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 74,761-74,790
Pages 3,679
Rows per page 30
Component
74,761-74,790 of 110,355
31
The chart uses a grouped bar structure to compare NXC-201 (green) against competitors (blue/red) across three categories: No BCMA, Yes BCMA, and Overall.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a structured comparison table to highlight clinical advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
35
The table displays clinical safety data for NXC-201, specifically focusing on Cytokine Release Syndrome and Immune cell associated Neurotoxicity.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
36
The slide highlights specific safety metrics for a competitor's product, likely to contrast with the presenter's own product profile.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
37
The diagram illustrates a dose-escalation process leading to the RP2D.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
39
Includes scientific diagrams of molecular pathways and bar/line charts showing efficacy data.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
44
Includes spider plots/swimmer-style plots for tumor response and bar charts for best percentage change.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
45
The slide uses a scatter plot to map clinical trials and a table to summarize treatment outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
46
The slide presents clinical data for a small sample size (n=4) in a highly pre-treated patient population.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
49
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
51
Includes technical diagrams of the drug delivery vehicle and comparative histology/survival data.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
53
Includes multiple citations and diagrams illustrating the mechanism of action and clinical efficacy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
56
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
57
The slide uses a serpentine process flow (1-5 left-to-right, 6-10 right-to-left).Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
58
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
60
The slide uses a bar chart to contrast the combined sales of two groups of drugs, implying a large market opportunity for TSTx.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
02
Headline doubles as action title with a positive-result takeaway; body is a pure bulleted summary with footnoted Lancet citations and Innoviva branding bottom-right.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
03
The diagram illustrates a randomized controlled trial structure.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
04
Flowchart shows patient progression from screening to dosing and categorization by infection site.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
10
The slide uses a combination of a text-based pipeline summary and a donut chart to visualize market penetration.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
09
Includes pro forma adjustments for exited businesses and geographies.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
11
The table highlights significant restructuring charges impacting GAAP results in Q3 2023.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
12
Non-GAAP measures. See reconciliation for GAAP to non-GAAP in Appendix. Drawings not to scale.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
13
The slide presents two metrics: 'Change in cash/investments' (table) and 'Ongoing cash burn' (bar chart), with detailed footnotes explaining adjustments.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
15
Includes footnotes regarding pro forma adjustments and cash definitions.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
16
Invitae | Results Presentation Deck | 27 slidesInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
20
Includes footnotes regarding company realignment and exited businesses.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations 1 hit
21
Includes footnotes regarding company realignment and rounding.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations 1 hit
22
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations 1 hit
23
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations 1 hit